Untargeted Metabolomic Analysis of the Effects and Mechanism of Nuciferine Treatment on Rats With Nonalcoholic Fatty Liver Disease

Huantian Cui¹, Yuting Li², Min Cao³, Jiabao Liao⁴, Xiangguo Liu¹, Jing Miao⁵, Hui Fu³, Ruwen Song⁶, Weibo Wen⁷, Zhaiyi Zhang³* and Hongwu Wang²*

¹ Shandong Provincial Key Laboratory of Animal Cell and Developmental Biology, School of Life Sciences, Shandong University, Qingdao, China, ² College of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China, ³ College of Integrated Chinese and Western Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China, ⁴ Department of Emergency, Jiaxing Hospital of Traditional Chinese Medicine, Jiaxing, China, ⁵ Department of Integrated Traditional and Western Medicine, Tianjin Second People’s Hospital, Tianjin, China, ⁶ College of Management, Tianjin University of Traditional Chinese Medicine, Tianjin, China, ⁷ Yunnan Provincial Hospital of Traditional Chinese Medicine, Kunming, China

Metabolomic analysis has been used to characterize the effects and mechanisms of drugs for nonalcoholic fatty liver disease (NAFLD) at the metabolic level. Nuciferine is an active component derived from folium nelumbinis and has been demonstrated to have beneficial effects on a high-fat diet (HFD) induced hepatic steatosis model. However, the effect of the altered metabolites of nuciferine on NAFLD has not yet been elucidated. In this study, we established a NAFLD rat model using HFD and treated with nuciferine. The lipid content levels, pro-inflammatory cytokines, and oxidative stress were investigated to assess the therapeutic effects of nuciferine. Additionally, the metabolic regulatory mechanisms of nuciferine on NAFLD were analyzed using untargeted metabolomics. Gene expression of the key enzymes related to the changed metabolic pathways following nuciferine intervention was also investigated. The results showed that nuciferine treatment significantly reduced the body weight, levels of lipids, and liver enzymes in the blood and improved the hepatic steatosis in the NAFLD rat model. Nuciferine treatment also increased the activities of superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) and decreased the levels of methane dicarboxylic aldehyde (MDA) in the liver. Nuciferine treatment decreased the serum levels of interleukin (IL)-6, IL-1β, and tumor necrosis factor-alpha (TNF-α) and upregulated the gene expression of IL-6, IL-1β, and TNF-α in the liver. Metabolomic analysis indicated a metabolism disorder in the NAFLD rat model reflected in a dysfunction of the glycerophospholipid, linoleic acid, alpha-linolenic acid, arginine and proline metabolism. Conversely, treatment with nuciferine improved the metabolic disorder in the NAFLD rat model. Nuciferine treatment also regulated the gene expression of key enzymes related to the glycerophospholipid, linoleic acid, and alpha-linolenic acid metabolism pathways in the liver. In conclusion, our study demonstrated an amelioration of the metabolic disorders following nuciferine treatment in NAFLD rat model. Our study contributes to the understanding of the effects and mechanisms of drugs for complex diseases using metabolomic analysis and experimental approaches.

Keywords: nonalcoholic fatty liver disease, nuciferine, metabolic disorder, metabolomic analysis
INTRODUCTION

Nonalcoholic fatty liver disease (NAFLD) is a chronic metabolic disease that is characterized by steatosis of the hepatocytes and dyslipidemia. Prolonged NAFLD could cause chronic metabolic diseases, including diabetes, liver fibrosis, liver cirrhosis, and hepatocellular carcinoma (HCC) (Wilkins et al., 2013; Masarone et al., 2014). Currently, the prevalence of NAFLD is becoming a global health concern. Epidemiology studies showed that the morbidity of NAFLD is 20–30% worldwide and could reach up to 75% in the obese population (Younossi et al., 2019).

Metabolomics can assist with screening the modifications to the endogenous metabolites in the disease models in order to understand the pathogenesis of diseases at the metabolic level. The dysfunction of the metabolic processes in NAFLD has been reviewed previously (Yu et al., 2017). In addition, metabolomics could provide a systematic view of the metabolites in the presence or absence of treatment and further clarify the potential mechanisms associated with this treatment. Quercetin could ameliorate NAFLD in rats via regulating the alphalinolenic acid, linoleic acid, arachidonic acid (AA), and bile acid metabolism pathways (Xu et al., 2019). Silybin could modulate the lipid, polyol, and amino acid metabolisms, as well as the urea and the tricarboxylic acid cycles in a NAFLD mouse model (Sun et al., 2020).

Nuciferine, an active component derived from folium nelumbinis, has been demonstrated to ameliorate dyslipidemia and regulate the expression of genes involved in lipogenesis, free fatty acid (FFA) β-oxidation, FFA infiltration, inflammation and oxidative stress on a high-fat diet (HFD)-induced hepatic steatosis model (Guo et al., 2013). In addition, studies have shown the beneficial effects of nuciferine on diabetic rats by regulating lipid metabolism (Ning et al., 2019). In vitro studies also revealed that nuciferine inhibited lipid accumulation and downregulated the expression of Per-Arnt-Sim Kinase (PASK) in oleic acid-induced hepatic steatosis in HepG2 cells (Zhang et al., 2015). However, the altered metabolites of nuciferine on NAFLD were poorly studied.

In this study, we established a NAFLD rat (Rattus norvegicus) model using HFD and treated with nuciferine. The therapeutic effects of nuciferine on NAFLD were evaluated by investigating the levels of lipid contents, pro-inflammatory cytokines, and oxidative stress. Additionally, untargeted metabolomic was used to analyze the metabolic regulatory mechanisms of nuciferine on NAFLD.

MATERIALS AND METHODS

Reagents

Nuciferine (C_{19}H_{23}NO_{5}; molecular weight, 295.38 Da; purity ≥ 98%) was purchased from Sichuan Weikeqi Biological Technology Co., Ltd. (Sichuan, China). HFD (17.7% sucrose, 17.7% fructose, 19.4% protein, and 40% fat) was obtained from Beijing Huafukang Bioscience Co., Ltd. (Beijing, China). Triglyceride (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), aspartate aminotransferase (AST), alanine aminotransferase (ALT), superoxide dismutase (SOD), methane dicarboxylic aldehyde (MDA), and glutathione peroxidase (GSH-Px) assay kits test kits were obtained from TianGen Biotechnology Co., Ltd. (Beijing, China). Rat interleukin (IL)-6, IL-1β, and tumor necrosis factor-alpha (TNF-α) enzyme-linked immunosorbent assay (ELISA) kits were obtained from Shanghai BlueGene Biotech Co., Ltd. (Shanghai, China).

Induction of NAFLD Rat Model

The NAFLD model was established as previously described (Li et al., 2020). Briefly, rats received HFD containing 26% carbohydrate (sucrose as carbohydrate source), 26% protein, and 35% fat for 12 weeks. Lard, rich in saturated fatty acids, was used as the source of fat in the HFD.

Animals and Treatment

Male Sprague-Dawley (SD) rats, 6–8 weeks old and 190–210 g weight, were purchased from Huafukang Animal Co., Ltd. (Beijing, China). They were housed in a controlled environment (12-h light/dark cycle, 21 ± 2°C with a relative humidity of 45 ± 10%) with ad libitum access to food and water. All animal experiments were approved by the Animal Ethics Committee at Tianjin University of Traditional Chinese Medicine.

After the acclimatization for 3 days, all animals were randomly divided into 3 groups (n = 10): control, experimental model, and nuciferine-treated groups. Rats in the control group were fed with standard laboratory chow containing 59.4% carbohydrate (cereal grain as the main carbohydrate source), 20% protein, and 4.8% fat and the other groups were given HFD to generate a NAFLD model. After 4 weeks of HFD treatment, rats in the nuciferine-treated group received a gavage of nuciferine (20 mg/kg body weight) once per day for 8 weeks (Wang et al., 2016; Ye et al., 2018), meanwhile, the same volume of saline solution was given intragastrically in the control and experimental model groups once per day for 8 weeks. The liver index was investigated at the end of 8 weeks after nuciferine treatment. The liver index was calculated using the following formula: liver index (%) = liver weight (g)/body weight (g) × 100 (Figure 1).

Serum Biochemical Markers Assay

Serum samples were collected at both week 4 and week 12 after HFD treatment for the biochemical assays. Briefly, rats were anesthetized with 10% chloral hydrate solution (0.3 ml/100g body weight, intraperitoneally) and blood was harvested by a capillary glass tube from the inner canthus. The serum was obtained by centrifuging at 3,000 rpm for 15 min. The levels of serum ALT, AST, TG, TC, HDL-C, and LDL-C were assayed according to the manufacturer’s instructions provided by Nanjing Jiancheng Biological Engineering Institute (Nanjing, China).
China) and the absorbance value was detected using a microplate reader (Varioskan Flash, Thermo Fisher, Massachusetts, USA).

**H&E Staining**
At the end of 12 weeks following nuciferine treatment, the rats were euthanized and the rat livers were removed immediately and fixed in 10% formalin, dehydrated, and embedded in paraffin wax. The tissues were cut into 5 µm sections using a microtome (RM2125, Leica, Buffalo Grove, USA). Sections were subsequently stained with hematoxylin and eosin (H&E) as previously described (Cui et al., 2017). The extent of steatosis, lobular inflammation and hepatocyte ballooning was determined using the NAFLD activity score (NAS) (Kobyliak and Abenavoli, 2014). Scores ranged from 0 to 8 (total score), representing the sum of the scores for the severity of steatosis, lobular inflammation, and hepatocyte ballooning (Table 1).

**Oil Red O Staining**
Livers were sectioned using a sliding vibratome (CM3050S, Leica, Buffalo Grove, USA) to obtain the coronal cryostat sections (20 µm thick). The sections were then stained with Oil Red O following the manufacturer's instructions. The staining extent of Oil Red O was analyzed and quantified using Image J. The integrated optical density (IOD) was then observed. The mean optical density (MOD) was calculated using the following formula: MOD = IOD/sum area.

**Liver Biochemical Analysis**
The liver tissues (0.1 g) were weighed and immersed in 900 µl normal saline followed by ultrasonic trituration and centrifugation at 3,000 rpm for 15 min to obtain liver tissue homogenates. The obtained supernatants were used to measure the SOD and GSH-Px activities and the MDA level according to the manufacturer's instructions provided by Nanjing Jiancheng Biological Engineering Institute (Nanjing, China).

**Cytokine Quantification by Enzyme-Linked Immunosorbent Assay (ELISA)**
Following 12 weeks of nuciferine treatment, the levels of IL-6, IL-1β, and TNF-α in the serum were measured using ELISA according to the manufacturer's instructions (Shanghai BlueGene Biotech Co., Ltd. China).

**RNA Isolation and Real-Time Reverse Transcription Quantitative Polymerase Chain Reaction (qPCR)**
Total RNA was isolated from the rat livers using an RNA extraction kit (TianGen Biotechnology Co., Ltd. Beijing, China). The first-strand cDNA was synthesized using 1 µg of total RNA according to the manufacturer’s instructions (TianGen Biotechnology Co., Ltd. Beijing, China). Real-time reverse transcription quantitative polymerase chain reaction (qPCR) was used to detect the expression of IL-6, IL-1β, TNF-α, phosphatidylethanolamine N-methyltransferase (PEMT), lecithin cholesterol acyltransferase (LCAT), phosphatidylserine synthase (PTDSS) 1, PTDSS2, phospholipase A2 (PLA2), fatty acid desaturase 2 (FADS2), CYP (cytochrome P-450) 2C, CYP2E1, CYP3A4, and arginase 2 (ARG2) in the liver as previously described (Cui et al., 2018). All samples were performed in triplicate and detected using a BioRad iQ5 Detection System. β-actin was used as a loading control. Quantification was performed using the 2^ΔΔCT method (Livak and Schmittgen, 2002). The sequences of the primers were listed in Table 2.

![FIGURE 1](image-url) | Overview of the experimental design for all groups.

---

**TABLE 1 | NAFLD Activity Score (NAS) (Kobyliak and Abenavoli, 2014).**

| Feature          | Score | Description                      |
|------------------|-------|----------------------------------|
| Steatosis        | 0     | 0–5% hepatocytes involved        |
|                  | 1     | 5–33% hepatocytes involved       |
|                  | 2     | 33–66% hepatocytes involved      |
|                  | 3     | >66% hepatocytes involved        |
| Hepatocyte ballooning | 0     | none                             |
|                  | 1     | Few; inapparent                  |
|                  | 2     | Easily noted; many               |
| Lobular inflammation | 0     | None                             |
|                  | 1     | <2 foci per x 200 field          |
|                  | 2     | 2–4 foci per x 200 field         |
|                  | 3     | >4 foci per x 200 field          |

The extent of NAFLD was evaluated by NAS. The score ranged from 0 to 8 (total score), representing the sum of scores of steatosis, hepatocyte ballooning, and lobular inflammation.
Metabolomics Study
The changes observed in the metabolites in serum following nuciferine treatment for 12 weeks were screened using liquid chromatography–mass spectrometry (LC-MS) (King et al., 2019). The detailed protocols used for sample preparation, LC-MS and data analysis are described below.

Sample Preparation
Ten μl of 2-chloro-1-phenylalanine (0.3 mg/ml) and Lyso PC17:0 (0.01 mg/ml) were dissolved in methanol and added to 100 μl of the serum samples. Subsequently, 300 μl of the protein precipitation solution containing methanol and acetonitrile (2/1, v/v) was added to each sample, followed by vortexing for 1 min. The mixture was then ultrasonicated in ice-cold water for 10 min and was incubated at −20°C for 30 min. Following incubation, the mixture was centrifuged at 13,000 rpm for 10 min and 300 μl of supernatant was collected, dried, and redissolved in 400 μl of a methanol/water solution (1/4, v/v). Following redissolving, the samples were centrifuged at 13,000 rpm for 10 min and 150 μl of supernatant was collected and filtered using a 0.22-μm filter and stored at −80°C before LC-MS analysis. Samples used for quality control (QC) were prepared by mixing aliquots of all samples in the same volume.

Liquid Chromatography–Mass Spectrometry
Metabolic profiling using electrospray ionization (ESI)-positive and ESI-negative ion modes for each sample was analyzed using the ACQUITY UHPLC system (Waters Corporation, Milford, USA) and the AB SCIEX Triple TOF 5600 system (AB SCIEX, Framingham, MA). An ACQUITY UPLC BEH C18 column (100 mm × 2.1 mm, 1.7 um) was used for the analytes with both positive and negative modes. The column temperature was maintained at 45°C. The chromatographic analysis of each sample was conducted with the mobile phase, including (A) water (containing 0.1% formic acid, v/v) and (B) methanol (containing 0.1% formic acid, v/v). The flow rate of the mobile phase was 0.25 ml/min and the injection volume was 2 μl. Separation was conducted as follows: 0 min, 2% B; 2 min, 2% B; 7 min, 98% B; 14 min, 98% B; 14.1 min, 2% B; and 16 min, 2% B.

Data acquisition was performed for both positive and negative ionization scan modes (m/z ranges from 100 to 1,200) via the ESI source. The detailed parameters of mass spectrometry (MS) for the positive ionization mode were as follows: spray voltage of 3,500 V, probe heater temperature at 300°C (+), sheath gas flow rate of 30 arbitrary units, auxiliary gas flow rate of 10 arbitrary units and capillary temperature at 320°C. The detailed parameters of MS for the negative ionization mode were as follows: spray voltage of 3,500 V, probe heater temperature at 350°C, sheath gas flow rate of 30 arbitrary units, auxiliary gas flow rate of 10 arbitrary units, and capillary temperature at 320°C. The QCs were injected every 10 samples throughout the analytical run to ensure the data accuracy.

Data Processing and Analysis
The acquired LC-MS raw data were analyzed using the Progenesis QI software (Nonlinear Dynamics, Newcastle, UK) to obtain three-dimensional data, including m/z, peak retention time and peak intensities. The primary parameters were set as follows: precursor tolerance, 5 ppm; product tolerance, 10 ppm; and product ion threshold, 5%. The metabolites were identified and detected using the Human Metabolome Database (HMDB)a, Lipidmaps (v2.3),b and METLINc databases. Subsequently, the peaks with a missing value (ion intensity = 0) in more than 50% of samples were filtered out. The metabolites were scored based on the three-dimensional data and metabolites with a compound score less than 30 were screened out.

The metabolic alterations occurring between the control and the experimental model group as well as between the experimental model group and the nuciferine-treated group were visualized using the principle component analysis (PCA) and the orthogonal partial least squares discriminant analysis (OPLS-DA) models (Kind et al., 2009). Seven-round cross-validation and 200 times modeling for the response permutation testing (RPT) were used to guard against overfitting in the analysis models based on the R² and Q² values. Variable influence on projection (VIP) values for each variable were obtained from the OPLS-DA model. The normalized peak areas for each metabolite were represented as mean ± standard deviation (mean ± SD) and were analyzed via a two-tailed Student’s t-test. Metabolites with a VIP > 1 and p < 0.05 among each group were considered to be differential metabolites. Differential metabolites in the control and the experimental model groups with a fold change (FC) > 1.25 or

---

**TABLE 2** Primer sequences of target genes for rats.

| Genes  | Primer sequence (5′→3′)                  |
|--------|-----------------------------------------|
| β-actin| Forward: TCTTCAGGCTCTTCTCTG             |
|        | Reverse: CACACAGATCTTCGCGTC             |
| IL−6   | Forward: CTCATTGTCTCTCGAGCCCA           |
|        | Reverse: TQAAGTAGAGAGGAGCATCGG          |
| IL−1β  | Forward: GGAGTAGAGAGGACTCTGA            |
|        | Reverse: TGTGCTGCTGCTGCTTCCT            |
| TNF−α  | Forward: GAGCAAGAGAAAGCATGATCC          |
|        | Reverse: TAGACAAGAGAGGCTGGTGG           |
| PEMT   | Forward: ATGTGTAAGAGGTTGGAAG            |
|        | Reverse: AGGCCAGAGGAGATAAGTGT           |
| LCAT   | Forward: ACTACAGAAGGCTGGCGAAGA          |
|        | Reverse: AGCCATCGAAATGGTGTC             |
| PLA2   | Forward: AAAAGAGGAGGCGCTTGAGA           |
|        | Reverse: TATGCAACGTGCTGAGAACAGAGAG     |
| PTSS1  | Forward: CAGGAATGATGAAAGAGGGCGATG       |
|        | Reverse: ATGAGTAGACTCGCTGGGAAG          |
| PTSS2  | Forward: TTGGACCTCACAGGCGAAG            |
|        | Reverse: GAATGTGTCAGCTGCTGGCAG          |
| FADS2  | Forward: ATGGCTGCTGACAACCGAGAG         |
|        | Reverse: AGTTGAGGAAAAACCGGCT            |
| CYP2C  | Forward: AAGCAAGAGGCGATCATCTCT          |
|        | Reverse: AGGCAAGAGGAAAGACCCCAA          |
| CYP3A4 | Forward: TTGGATGAGAGGCTGCAAA           |
|        | Reverse: CTTTTCATCAATGGGCCACT           |
| CYP2E1 | Forward: TQAAGGAGAGGAGGCTGCCAGA         |
|        | Reverse: TCATGAGTAGTGCTGCTG            |
| ARG2   | Forward: TTGGTATCTGGCTGCTGAAGG          |
|        | Reverse: CATGACATCAGCGAGATG             |
FC < 0.80 were selected for the metabolic pathway analysis. The metabolic pathways for the differential metabolites in the control and model groups were analyzed using the MetaboAnalyst software. The pathway library for the Kyoto Encyclopedia of Genes and Genomes (KEGG) was selected (Sun et al., 2020).

Statistics
All data are reported as the mean ± SD for the independent experiments. Statistical differences between the experimental groups were examined using the analysis of variance (ANOVA) and SPSS software, version 20.0. A p-value < 0.05 was considered statistically significant. Curve fitting was performed using the GraphPad Prism 5 software.

RESULTS

Effects of Nuciferine on HFD-Induced NAFLD Model Rats
Following 4 weeks of HFD treatment, the body weight of the rats was significantly increased in the experimental model and the nuciferine groups as compared to the control group (p < 0.05, respectively, Table 3). Furthermore, the serum levels of TG, TC, LDL-C, AST, and ALT (p < 0.01, respectively, Tables 4 and 5) were increased and the level of HDL-C (p < 0.05, Table 4) in the serum was decreased in the experimental model and nuciferine groups as compared to that of the control group.

After 8 weeks of nuciferine treatment, the body weight (p < 0.05) and liver index (p < 0.05) were increased in the experimental model group as compared to the control group. Differently, nuciferine treatment significantly decreased the body weight (p < 0.05) and liver index (p < 0.05, Table 3) in the NAFLD rat model. In addition, the serum levels of TG, TC, LDL-C, AST, and ALT (p < 0.01, respectively, Tables 4 and 5) were increased and the level of HDL-C (p < 0.05, Table 4) in the serum was decreased in the experimental model group as compared to that of the control group. Nuciferine treatment significantly decreased the serum levels of TG, TC, LDL-C, AST, and ALT (p < 0.01, p < 0.05, p < 0.05, p < 0.01, and p < 0.01, respectively, Tables 4 and 5) as compared to the experimental model group.

H&E staining revealed enlarged hepatocytes with severe microvesicular steatosis and ballooning as well as lobular inflammation in the experimental model group, which resulted in a higher NAS compared with the control group (p < 0.01, Figures 2A, B). Furthermore, Oil Red O staining confirmed hepatosteatosis and increased lipid deposition in the experimental model group (p < 0.01, Figures 2C, D). Liver sections in the nuciferine-treated rats showed only moderate steatosis, ballooning, lower NAS (p < 0.01, Figures 2A, B) and less lipid-loaded hepatocytes (p < 0.01, Figures 2C, D) as compared to the experimental model group.

Anti-Oxidative and Anti-Inflammatory Effects of Nuciferine on HFD-Induced NAFLD Rat Model
Previous studies have shown that oxidative stress plays an important role in the progression of NAFLD (Braud et al., 2017). Thus, we further investigated whether nuciferine inhibited oxidative stress in the NAFLD rats. The results showed that the activities of SOD and GSH-Px were lower and the level of MDA was higher in the experimental model group as compared to the control group (p < 0.01, respectively, Table 6),

---

**TABLE 3 | The effects of nuciferine treatment on body weight and liver index.**

| Group      | Body weight (g) | Liver index (%) |
|------------|-----------------|-----------------|
| **4 weeks after HFD treatment** |
| Control    | 292.0 ± 22.3    | 67.44 ± 7.46    |
| Model      | 321.9 ± 27.3*   | 116.15 ± 11.14*|
| Nuciferine | 324.2 ± 30.4*   | 116.15 ± 12.67*|
| **12 weeks after HFD treatment** |
| Control    | 425.0 ± 37.7    | 2.82 ± 0.25     |
| Model      | 461.6 ± 35.0*   | 3.28 ± 0.37*    |
| Nuciferine | 419.5 ± 43.8*   | 2.91 ± 0.29*    |

Control, experimental model, and nuciferine-treated (n = 10 per group) groups. Data are presented as the mean ± SD. *p < 0.05 as compared to the control group; **p < 0.01 as compared to the experimental model group.

---

**TABLE 4 | Changes in blood lipid levels in NAFLD model rats.**

| Group      | TG (mmol/L) | TC (mmol/L) | LDL-C (mmol/L) | HDL-C (mmol/L) |
|------------|-------------|-------------|----------------|----------------|
| **4 weeks after HFD treatment** |
| Control    | 1.94 ± 0.28 | 4.40 ± 0.87 | 0.83 ± 0.10    | 1.93 ± 0.35    |
| Model      | 5.42 ± 0.65** | 6.03 ± 0.95** | 1.13 ± 0.30**  | 1.65 ± 0.21**  |
| Nuciferine | 5.37 ± 0.91** | 5.91 ± 0.94** | 1.16 ± 0.24**  | 1.61 ± 0.26**  |
| **12 weeks after HFD treatment** |
| Control    | 1.92 ± 0.30 | 4.46 ± 1.26 | 0.85 ± 0.09    | 2.02 ± 0.56    |
| Model      | 8.74 ± 2.04** | 7.60 ± 1.03** | 1.41 ± 0.25**  | 1.49 ± 0.15**  |
| Nuciferine | 4.22 ± 1.51** | 5.66 ± 1.51* | 0.93 ± 0.36*   | 1.84 ± 0.37*   |

Control, experimental model, and nuciferine-treated (n = 10 per group) groups. Data are presented as the mean ± SD. *p < 0.05 as compared to the control group; **p < 0.01 as compared to the control group; ***p < 0.01 as compared to the experimental model group.

---

**TABLE 5 | Changes in blood ALT and AST levels in NAFLD model rats.**

| Group      | ALT (U/L) | AST (U/L) |
|------------|-----------|-----------|
| **4 weeks after HFD treatment** |
| Control    | 50.82 ± 7.24 | 70.97 ± 6.39 |
| Model      | 82.23 ± 11.04** | 120.56 ± 11.14** |
| Nuciferine | 82.43 ± 8.83** | 116.15 ± 12.67** |
| **12 weeks after HFD treatment** |
| Control    | 48.89 ± 6.12 | 67.44 ± 7.46 |
| Model      | 123.18 ± 11.31** | 190.92 ± 17.26** |
| Nuciferine | 65.74 ± 6.54** | 90.46 ± 9.38** |

Control, experimental model, and nuciferine-treated (n = 10 per group) groups. Data are presented as the mean ± SD. **p < 0.01 as compared to the control group; ***p < 0.01 as compared to the experimental model group.
downregulated the expression of IL-6 and (in the experimental model group as compared to the control group (p < 0.01, and serum as compared to the experimental model group (p < 0.05).

The levels of IL-6, IL-1β, and TNF-α in the serum were investigated using ELISA. The levels of IL-6, IL-1β, and TNF-α were higher in the experimental model group compared to that of the control group (p < 0.01, respectively, Figure 3A). Nuciferine treatment decreased the levels of IL-6, IL-1β, and TNF-α in the serum as compared to the experimental model group (p < 0.05, p < 0.01, and p < 0.01, respectively, Figure 3A). We also investigated the relative mRNA expression of IL-6, IL-1β, and TNF-α in the liver using qPCR. The expression of IL-6, IL-1β, and TNF-α was higher in the experimental model group as compared to the control group (p < 0.01, respectively, Figure 3B), whereas nuciferine treatment downregulated the expression of IL-6, IL-1β, and TNF-α as compared to the experimental model group (p < 0.01, p < 0.05, and p < 0.01, respectively, Figure 3B).

Multivariate Analysis of Serum Metabolomics

The typical based peak intensity (BPI) chromatograms of the serum samples were analyzed in positive and negative modes, respectively (Figures 1 and 2). Endogenous markers in all groups were optimally separated after 16 min. PCA showed a clear group separation between the control and the experimental model groups, while an unclear distinction was obtained between the experimental model and the nuciferine-treated groups, according to the PCA model. Therefore, an OPLS-DA was performed to analyze the metabolomics data. The OPLS-DA models indicated significant metabolic variations between the control group and the experimental model group as well as between the experimental model group and the nuciferine-treated group (Figure 4). Likewise, seven-round cross-validation and 200 times of RPT showed that the OPLS-DA models were robust. When comparing the control group with the experimental model group, the R² and Q² values in the OPLS-DA model were 0.219 and −0.532, respectively. However, when comparing the experimental model group with the nuciferine-treated group, the R² and Q² values in the OPLS-DA model were 0.668 and −0.973, respectively (Figure 4).

Identification of Differential Metabolites

Generally, 20 differential metabolites between the control group and the experimental model group and 18 differential metabolites between the experimental model group and the nuciferine-treated group were identified (VIP > 1 and p < 0.05, Figure 5). Differential metabolites between the experimental model and the control groups, phosphatidylcholine (PC), dihomo-gamma-linolenate, rumenic acid, linoleic acid, 1-acylglycerophosphocholine, alpha-linolenic acid, and eicosapentaenoic acid (EPA) were decreased. Furthermore, 12(R)-HETE, L-leucine, L-valine, L-isoleucine, phosphatidylethanolamine (PE), glyceryl phosphorylethanolamine, L-proline, L-arginine, L-tryptophan, 2-hydroxycinnamic acid, trans-cinnamic acid, nicotyrine, and THTC were increased (Table 7).

---

| GROUP               | SOD (U/mgprot) | MDA (mmol/mgprot) | GSH-Px (U/mgprot) |
|---------------------|----------------|-------------------|-------------------|
| Control             | 184.18 ± 16.49 | 2.43 ± 0.43       | 69.21 ± 1.95      |
| Model               | 134.45 ± 29.44*| 16.55 ± 1.66**    | 53.55 ± 5.80**    |
| Nuciferine          | 161.07 ± 16.30*| 7.57 ± 2.41**     | 60.41 ± 8.28*     |

Control, experimental model, and nuciferine-treated (n = 10 per group) groups. Data are presented as the mean ± SD. **p < 0.01 as compared to the control group; *, p < 0.05 as compared to the experimental model group; †*, p < 0.01 as compared to the experimental model group.
Pathway Analysis of Differential Metabolites

The significantly changed metabolic pathways in the NAFLD model rats were analyzed using Metabo Analyst. Pathways with a p-value of less than 0.05 and an impact value of more than 0.10 were considered to be the significant pathways. Fifteen metabolic pathways were identified to be related to NAFLD. Among these pathways, linoleic acid metabolism with an impact value of 1.00 and p-value of 0.038, alpha-linolenic acid metabolism with impact value of 0.33 and p-value of 0.006, glycerophospholipid metabolism with impact value of 0.24 and p-value of 0.018 and arginine and proline metabolism with impact value of 0.13 and p-value of 0.048 were selected as the significant pathways (Figure 6). The summary schematic for the significant pathways was displayed in Figure 7. Moreover, the gene expression of the key enzymes related to the significant pathways was also investigated. The expression of PLA2 (p < 0.05), PTDSS1 (p < 0.01), PTDSS2 (p < 0.01), FADS2 (p < 0.01), CYP2C (p < 0.01), CYP2E1 (p < 0.01), and CYP3A4 (p < 0.01) was higher and the expression of PEMT (p < 0.05), LCAT (p < 0.01), and ARG2 (p < 0.01) was lower in the experimental model group as compared to the control group (Figure 8). On the other hand, nuciferine treatment downregulated the expression of PLA2 (p < 0.05), PTDSS2 (p < 0.05), FADS2 (p < 0.01), CYP2E1 (p < 0.05), and CYP3A4 (p < 0.01), while it upregulated the expression of PEMT (p < 0.05) and LCAT (p < 0.01) as compared to the experimental model group (Figure 8).

DISCUSSION

In this study, we established a NAFLD rat model using HFD. Consistent with previous studies (Jiang et al., 2016), our results showed that the body weight, lipid contents, and liver enzymes in the serum of animals were increased in rats receiving HFD. Moreover, rats in the experimental model group exhibited enlarged hepatocytes with severe microvesicular steatosis. Nuciferine showed a remarkable effect on the NAFLD, reflecting an improvement in hyperlipidemia and liver steatosis in the NAFLD model rats.

According to the two-hit hypothesis presented by Christopher Day and Oliver James, the hepatocytes receive first hits when excessive lipid content is accumulated in the liver with a consequent dysfunction of lipid metabolism. Moreover, dysfunction of the lipid metabolism could trigger oxidative stress and cellular damage in the hepatocytes (Chen et al., 2008). The results of the current study showed that the activities of SOD and GSH-Px were increased and the level of MDA in the liver was decreased following nuciferine treatment. MDA was the end product of lipid peroxidation and excessive O2 induced lipid peroxidation and caused a second hit to the hepatocytes (Vander Heiden et al., 1997). SOD and GSH-Px are antioxidant enzymes that could protect the hepatocytes from oxidative stress and cellular damage (Xie et al., 2019).

Metabolomic analysis showed that the glycerophospholipid, linoleic acid, alpha-linolenic acid, as well as arginine and proline metabolism pathways were selected as significant affected pathways in the NAFLD rat model based on their higher impact value. As an important part of biological membranes, the glycerophospholipid metabolism was involved in many biological processes such as membrane fusion, pinocytosis, and membrane transport. Therefore, dysfunction of the glycerophospholipid metabolism could negatively affect the energy metabolism in the liver (Mesens et al., 2012). Our results showed that the levels of PC and 1-acylglycerophosphocholine were decreased, whereas PE and glycerylphosphorylethanolamine were increased in the NAFLD rat model. Nuciferine treatment increased the levels of PC and 1-acylglycerophosphocholine.
acylglycerophosphocholine in the serum. PCs account for 40–50% of the total phospholipids; therefore, they are the most abundant glycerophospholipids in mammalian cells. PEs account for 40% of the total phospholipids and were primarily found in the mitochondrial membrane (Van Der Veen et al., 2017). The ratio of PC to PE was decreased in the NAFLD-affected patients (Li et al., 2006). Further studies have shown that PC was significantly decreased and PE was increased in HFD-induced NAFLD models. The decreased PC to PE ratio impaired the cell membrane component and induced the permeability of the hepatocytes, which accelerated liver injury (Calzada et al., 2016). Although nuciferine treatment did not affect the PE levels in the NAFLD models, nuciferine could induce the PC to PE ratio to improve the lipid metabolism in NAFLD. Studies have demonstrated the beneficial effects of PC on hepatic inflammation. In LPS induced inflammation rat models, the combination treatment of PC and hydrocortisone could decrease the pro-inflammatory cytokine levels in serum and alleviate the infiltration of inflammatory cells in the liver (Boza et al., 2005). Similarly, our results showed that nuciferine could ameliorate the inflammatory response in a NAFLD rat model. Furthermore, the expression of enzymes (PEMT, LCAT, PTDSS1, PTDSS2, and PLA2) involved in the glycerophospholipid metabolism of the liver was changed in NAFLD model rats and nuciferine treatment regulated the expression of PEMT, LCAT, PTDSS2 and PLA2. PC could be synthesized from choline or be transformed from PE under the catalysis of phosphatidylethanolamine N-methyltransferase (PEMT). NAFLD patients exhibited a lack of function of PEMT and the dysfunction in PEMT inhibited the transformation of PE to PC and caused the accumulation of PE (Araujo et al., 1998; Castro-Martínez et al., 2012). Lecithin–cholesterol acyltransferase (LCAT) participated in the transformation of PC to HDL-C. The expression of LCAT was decreased in the HFD-induced hyperlipidemia model (Zeng et al., 2016). Phospholipase A2 (PLA2) catalyzed the hydrolysis of PC to generate lysophosphatidylcholine (LPC). Excessive LPC induced apoptosis of the hepatocytes (Han et al.,

FIGURE 4 | Variable analysis of the metabolomics data in each group. (A, B) Score plots of PCA between the control group and the experimental model group and the experimental model group and the nuciferine-treated group; (C, D) Score plots of OPLS-DA between the control group and the experimental model group and the corresponding coefficient of loading plots; (E, F) Score plots of OPLS-DA between the experimental model group and the nuciferine-treated group and the corresponding coefficient of loading plots. Control, experimental model, and nuciferine-treated (n = 10 per group) groups.
2008). PE and PC were transformed into phosphatidylserine under the catalysis of phosphatidylserine synthase (PTDSS). Microarray analysis revealed that the expression of PTDSS was increased in diabetic model rats. Downregulation of PTDSS induced the levels of PC (Choi et al., 2012).

Linoleic acid and alpha-linolenic acid metabolisms are associated with metabolic syndrome. The levels of linoleic acid, dihomo-gamma-linolenate, rumenic acid and alpha-linolenic acid were decreased in the NAFLD rat model, whereas these metabolites exhibited opposite trends following nuciferine treatment. Linoleic acid, dihomo-gamma-linolenate, and alpha-linolenic acid are unsaturated fatty acids (UFAs) and have been demonstrated to have beneficial effects on metabolic disorders. Linoleic acid has been demonstrated a lipid-lowering effect through inducing the transformation of TC (Koo, 2013). Treatment of conjugated linoleic acid ameliorated obesity through reducing lipogenesis and increasing lipolysis and fat oxidation (Wang et al., 2017). Dietary oils rich in linoleic acid and alpha-linolenic acid improved the obesity-related glomerulopathy through reducing the visceral adiposity and

![FIGURE 5](image5.png)

FIGURE 5 | Numbers of the differential metabolites between the control group and the experimental model group and the nuciferine-treated group (Venn plot). (A) Decreased levels in the experimental model group as compared to the control group. (B) Elevated levels in the experimental model group as compared to the control group. (C) Elevated levels in the nuciferine-treated group as compared to the experimental model group. (D) Decreased levels in the nuciferine-treated group as compared to the experimental model group.

![FIGURE 6](image6.png)

FIGURE 6 | Pathway analysis for serum samples in the HFD-induced NAFLD rat model. (A) Linoleic acid metabolism, (B) alpha-linolenic acid metabolism, (C) glycerophospholipid metabolism, and (D) arginine and proline metabolism.

### TABLE 7 | The differential serum metabolites between the experimental groups.

| No. | Rt (min) | m/z | Formula | Metabolites | VIP M vs. C | VIP N vs. M | FC M vs. C | FC N vs. M | Trend M vs. C | Trend N vs. M | Pathway |
|-----|---------|-----|---------|------------|-------------|-------------|-------------|-------------|--------------|--------------|---------|
| 1   | 0.83    | 940.8140 | C_{68}H_{112}NO_{8}P | Phosphatidylcholine | 2.44 | 1.87 | 0.62 | 1.29 | ↓## | ↑* | c |
| 2   | 11.32   | 305.2484 | C_{18}H_{38}O_{2} | Dihomo-gamma-linolate | 1.08 | 1.44 | 0.52 | 1.49 | ↓### | ↑** | a |
| 3   | 0.71    | 281.2460 | C_{18}H_{32}O_{2} | Linoleic acid | 1.35 | 1.60 | 0.65 | 1.26 | ↓## | ↑* | a |
| 4   | 10.99   | 279.2327 | C_{18}H_{34}O_{2} | Rumenic acid | 4.89 | 6.01 | 0.33 | 2.03 | ↓## | ↑** | a |
| 5   | 10.50   | 277.2171 | C_{18}H_{30}O_{2} | Alpha-linolenic acid | 1.33 | 1.69 | 0.44 | 1.39 | ↓## | ↑** | a |
| 6   | 10.41   | 325.2901 | C_{18}H_{32}O_{2} | EPA (d5) | 3.59 | 2.86 | 0.85 | 1.05 | ↓## | ↑** | – |
| 7   | 9.43    | 319.2273 | C_{20}H_{32}O_{2} | 12(R)-HETE | 3.84 | 3.99 | 2.06 | 0.40 | ↓## | ↑* | b |
| 8   | 2.92    | 132.1014 | C_{5}H_{13}NO_{2} | L-leucine | 4.14 | 3.32 | 3.84 | 0.49 | ↓## | ↑* | – |
| 9   | 1.43    | 118.0860 | C_{5}H_{11}NO_{2} | L-valine | 2.97 | 2.37 | 3.15 | 0.50 | ↓## | ↑* | – |
| 10  | 2.69    | 132.1014 | C_{5}H_{11}NO_{2} | L-isoleucine | 3.15 | 2.48 | 2.48 | 0.51 | ↓## | ↑* | – |
| 11  | 10.58   | 766.4845 | C_{45}H_{70}NO_{8}P | Phosphatidylethanolamine | 1.41 | 1.24 | 1.39 | 0.86 | ↓## | ↑* | – |
| 12  | 10.49   | 570.3527 | C_{30}H_{52}NO_{7}P | 1-acylglycerophosphocholine | 1.26 | 1.06 | 0.34 | 2.24 | ↓## | ↑* | – |
| 13  | 6.60    | 216.0822 | C_{11}H_{16}NO_{2}P | Glycerophosphorylthanolamine | 1.10 | 1.88 | 3.21 | 0.73 | ↓## | ↑* | – |
| 14  | 1.06    | 116.0703 | C_{17}H_{34}NO_{2} | L-proline | 2.61 | 2.01 | 4.37 | 0.52 | ↓## | ↑* | – |
| 15  | 0.88    | 175.1181 | C_{18}H_{32}NO_{2} | L-arginine | 2.87 | 2.31 | 3.70 | 0.80 | ↓## | ↑* | – |
| 16  | 5.77    | 203.0816 | C_{11}H_{16}NO_{2} | L-tryptophan | 1.23 | 1.06 | 2.72 | 0.50 | ↓## | ↑* | – |
| 17  | 2.85    | 182.0804 | C_{17}H_{32}NO_{2} | 2-hydroxyacinnamic acid | 4.17 | 3.63 | 3.14 | 0.48 | ↓## | ↑* | – |
| 18  | 5.17    | 166.0855 | C_{17}H_{32}NO_{2} | Trans-cinnamic acid | 5.17 | 4.35 | 2.63 | 0.48 | ↓## | ↑* | – |
| 19  | 5.75    | 159.0909 | C_{12}H_{18}NO_{2} | Nicotyrine | 1.17 | 1.00 | 2.40 | 0.46 | ↓## | ↑* | – |
| 20  | 1.72    | 150.0576 | C_{12}H_{18}NO_{2} | THTC | 2.78 | 2.53 | 3.07 | 0.42 | ↓## | ↑* | – |
| 21  | 10.85   | 730.2405 | C_{18}H_{32}NO_{2} | Lacto-N-tetraose | 0.95 | 2.37 | 0.87 | 1.20 | ↓## | ↑* | – |
| 22  | 10.90   | 339.2871 | C_{12}H_{18}NO_{2} | 1,2,4-Nonadecanetriol | 0.96 | 3.02 | 0.96 | 1.23 | ↓## | ↑* | – |

*p < 0.05 as compared to the control group; **p < 0.01 as compared to the control group; *p < 0.05 as compared to the experimental model group; **p < 0.01 as compared to the experimental model group; ↑, content increased; ↓, content decreased; vs., versus; C, control group; M, experimental model group; N, nuciferine-treated group.
FIGURE 7 | Summary schematic of significant pathways in rats with NAFLD after nuciferine treatment. 12(13)-EpOME, (12R,13S)-(9Z)-12,13-epoxyoctadecenoic acid; 9(10)-EpOME, (9R,10S)-(12Z)-9,10-epoxyoctadecenoic acid; PEMT, phosphatidylethanolamine N-methyltransferase; LCAT, lecithin cholesterol acyltransferase; PLA2, phospholipase A2; PTDSS1, phosphatidylserine synthase 1; PTDSS2, phosphatidylserine synthase 2; FADS2, fatty acid desaturase 2; CYP2C, cytochrome P-450 2C; CYP2E1, cytochrome P-450 2E1; CYP3A4, cytochrome P-450 3A4; ARG2, arginase 2.

FIGURE 8 | Gene expression of PLA2, PTDSS2, FADS2, CYP2E1, and CYP3A4 was downregulated, while PEMT and LCAT was upregulated in liver after nuciferine treatment (fold to experimental model group). Control, experimental model, and nuciferine-treated (n = 6 per group) groups. Data are presented as mean ± SD. *p < 0.05 as compared to the control group; **p < 0.01 as compared to the control group; *p < 0.05 as compared to the experimental model group; **p < 0.01 as compared to the experimental model group.
glomerular damage (Caligiuri et al., 2014). The current results also showed that the gene expression related to linoleic acid (CYP2C, CYP2E1, and CYP3A4) and alpha-linolenic acid (FADS2) metabolism was changed in the NAFLD model group, whereas the expression of CYP2E1, CYP3A4, and FADS2 exhibited opposite trends following nuciferine treatment. Cytochrome P-450 (CYP) enzyme system, which was primarily expressed in the liver, involved several metabolic processes of endogenous and exogenous compounds and was demonstrated to be closely related to the progression of NAFLD (Bell et al., 2010). CYP2C, CYP2E1, and CYP3A4 catalyzed the oxidation of linoleic acid, generating 12(13)-EpOME and 9(10)-EpOME. The expression of CYP2C (Fisher et al., 2009), CYP2E1 (Bell et al., 2011) and CYP3A4 (Fisher et al., 2009) was upregulated in the liver of the NAFLD model. Increased activities of the CYP enzymes induced the peroxidation of the lipid contents and increased the levels of MDA in the hepatocytes (Bell et al., 2010). The anti-oxidative mechanisms of nuciferine in NAFLD might be related to inhibiting the expression of the CYP enzymes in the liver. Alpha-linolenic acid could be transformed into stearidonic acid under the catalysis of FADS2. The expression of FADS2 was upregulated in obese patients. FADS2 induced the inflammatory response in the adipose tissue, which also supported the anti-inflammatory properties of nuciferine in NAFLD (Vaittinen et al., 2015).

The metabolism of amino acids was an important component of NAFLD-related metabolic disorders. Levels of L-arginine and L-proline were increased in the NAFLD rat model, while nuciferine treatment decreased the L-proline levels. L-arginine transformed into L-ornithine and urea via the urea cycle to decrease ammonia. L-ornithine could transform into L-proline and, in turn, L-proline could transform into pyruvate to enter the citrate cycle. The dysfunction of arginine and proline metabolism has been observed in a NAFLD model (Sun et al., 2020). The current study also showed that the expression of ARG2 was upregulated in NAFLD model rats. ARG2 is a key enzyme in the urea cycle and catalyzes the transformation of L-arginine into L-ornithine. Dysfunction in the urea cycle induced the accumulation of L-arginine and caused hyperammonemia. High levels of blood ammonia could activate hepatic stellate cells to induce hepatic fibrosis and could contribute to NAFLD progression (Thomsen et al., 2018).

In conclusion, our study demonstrated the therapeutic effects of nuciferine in a NAFLD rat model. Untargeted metabolomic analysis indicated significant dysfunction in the glycerophospholipid, linoleic acid, alpha-linolenic acid, arginine, and proline metabolism pathways. The mechanism of nuciferine in NAFLD might be related to the improvement of these dysregulated metabolic pathways.

**DATA AVAILABILITY STATEMENT**

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

**ETHICS STATEMENT**

The animal study was reviewed and approved by Animal Ethics Committee in Tianjin University of TCM (SYXK2019-0006).

**AUTHOR CONTRIBUTIONS**

HC wrote the manuscript. HC, YL, MC, JL, and HF conducted animal experiments. YL, RS, and HC finished molecular bioassays. WW, JM, XL, HW, and ZZ provided technical guidance for the whole work. All authors contributed to the article and approved the submitted version.

**FUNDING**

This work was supported by National Science Foundation of China (81560772), Natural Science Foundation of Tianjin (17JCYJC42800), Science and Technology Projects in Key Fields of Traditional Chinese Medicine of Tianjin Municipal Health Commission (No.2020006), and Public Welfare Research Projects in Jiaxing (SQ2018001355).

**ACKNOWLEDGMENTS**

Wish the global epidemic of coronavirus disease 2019 ends soon!

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2020.00858/full#supplementary-material

**REFERENCES**

Araujo, L. M., De Oliveira, D. A., and Nunes, D. S. (1998). Liver and biliary ultrasonography in diabetic and non-diabetic obese women. *Diabetes Metab.* 24, 458–462. doi: 10.1177/014572179802400611

Bell, L. N., Temm, C. J., Saxena, R., Vuppalanchi, R., Schauer, P., Rabinovitz, M., et al. (2010). Bariatric surgery-induced weight loss reduces hepatic lipid peroxidation levels and affects hepatic cytochrome p-450 protein content. *Ann. Surg.* 251, 1041–1048. doi: 10.1097/lsa.0b013e3181fb572

Bell, L. N., Molleston, J. P., Morton, M. J., Klipsch, A., Saxena, R., Vuppalanchi, R., et al. (2011). Hepatic lipid peroxidation and cytochrome P-450 2E1 in pediatric nonalcoholic fatty liver disease and its subtypes. *J. Clin. Gastroenterol.* 45, 800–807. doi: 10.1097/MCG.0b013e31821377e4

Boza, C., Ruquelme, A., Ibanez, L., Duarte, I., Norero, E., Viviani, P., et al. (2005). Predictors of nonalcoholic steatohepatitis (NASH) in obese patients undergoing gastric bypass. *Obes. Surg.* 15, 1148–1153. doi: 10.1381/0960892055002347

Braud, L., Battault, S., Meyer, G., Nascimento, A., Gaillard, S., de Sousa, G., et al. (2017). Antioxidant properties of tea blunt ROS-dependent lipogenesis:
beneficial effect on hepatic steatosis in a high-fat-high-sucrose diet NAFLD obese rat model. J. Nutr. Biochem. 40, 95–104. doi: 10.1016/j.jnutbio.2016.07.012

Caligiuri, S. P., Blyth-Hansen, T., Love, K., Gregorevi, M., Taylor, C. G., Zahradka, P., et al. (2014). Evidence for the use of glomerulomegaly as a surrogate marker of glomerular damage and for alpha-linolenic acid-rich oils in the treatment of early obesity-related glomerulopathy in a diet-induced rodent model of obesity. Appl. Physiol. Nutr. Metab. 39, 951–959. doi: 10.1139/apnm-2013-0476

Calzada, E., Onguka, O., and Claypool, S. M. (2016). Phosphatidylethanolamine Metabolism in Health and Disease. Int. Rev. Cell Mol. Biol. 321, 29–88. doi: 10.1016/bs ircmb.2015.10.001

Castro-Martinez, M. G., Banderas-Lares, D. Z., Ramirez-Martinez, J. C., and Escobedo-de la Pena, J. (2012). Prevalence of nonalcoholic fatty liver disease in subjects with metabolic syndrome. Cir. Cir. 80, 128–133.

Chen, Z. W., Chen, L. Y., Dai, H. L., Chen, J. H., and Fang, L. Z. (2008). Relationship between alanine aminotransferase levels and metabolic syndrome in nonalcoholic fatty liver disease. J. Zhejiang Univ. Sci. B. 9, 616–622. doi: 10.1631/jzus.B0720016

Choi, S. A., Suh, H. J., Yun, J. W., and Choi, J. W. (2012). Differential gene expression in pancreatic tissues of streptozocin-induced diabetic rats and genetically diabetic mice in response to metformin treatment. Mol. Biol. Rep. 39, 8821–8835. doi: 10.1007/s11033-012-1746-1

Cui, H. T., Liu, Z., Wang, L., Bian, Y., Li, W., Zhou, H., et al. (2017). Icariin-treated human umbilical cord mesenchymal stem cells decrease chronic liver injury in mice. Cytotechnology 69, 19–28. doi: 10.1007/s10616-016-0034-7

Cui, H. T., Cai, Y., Wang, L., Jia, B., Li, J., Zhao, S., et al. (2018). Berberine Regulates Treg/Th17 Balance to Treat Ulcerative Colitis Through Modulating the Gut Microbiota in the Colon. Frontiol Pharmcol. 9, 571. doi: 10.3389/fphar.2018.00571

Ding, Y., Sun, X., Chen, Y., Deng, Y., and Qian, K. (2015). Epigallocatechin gallate Kind, T., Wohlgemuth, G., Lee, D. Y., Lu, Y., Palazoglu, M., Shahbaz, S., et al. (2020). Hua-Zhuo-Kai-Yu decoction inhibits apoptosis in nonalcoholic fatty liver disease. Tradit. Med. Res. 1. doi: 10.12032/TMR20200201157

Livik, K. J., and Schmitgen, T. D. (2002). Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25, 402–408. doi: 10.1006/meth.2001.1262

Masarone, M., Federico, A., Abenavoli, L., Loguercio, C., and Persico, M. (2014). Non alcoholic fatty liver: epidemiology and natural history. Rev. Recent Clin. Trials 9, 126–133. doi: 10.2174/157488710966614121611143

Mesens, N., Desmidt, M., Verheugen, G. R., Starcks, S., Damisch, S., De Vries, R., et al. (2012). Phospholipidosis in rats treated with amiodarone: serum biochemistry and whole genome micro-array analysis supporting the lipid traffic jam hypothesis and the subsequent rise of the biomarker BMP. Toxicol. Pathol. 40, 491–503. doi: 10.1177/0192623311432290

Ning, Q., Wang, Y., Zhang, Y., Shen, G. Z., Xie, Z. L., and Pang, J. (2019). Nuciferine prevents hepatic steatosis by regulating lipid metabolism in diabetic rat model. Open Life Sci. 14, 699–706. doi: 10.1515/biol-2019-0079

Park, S. Y., Shinzawa, K., Kim, S., Lee, M. S., Kun, W. C., et al. (2008). Kobyliak, N., and Abenavoli, L. (2014). The role of liver biopsy to assess non-alcoholic steatohepatitis induced by methionine- and choline-deficient diet in genetically diabetic mice. Eur. J. Pharmacol. 761, 405–412. doi: 10.1016/j.ejphar.2015.05.005

El-Din, S. H., Sabra, A. N., Hammam, O. A., Ebeid, F. A., and El-Lakkany, N. M. (2014). Pharmacological and antioxidant actions of garlic and/or onion in non-alcoholic fatty liver disease (NAFLD) in rats. J. Egypt Soc Parasitol. 44, 295–308. doi: 10.12816/0006468

Fisher, C. D., Lickteig, A. J., Augustine, L. M., Ranger-Moore, J., Jackson, J. P., Ferguson, S. S., et al. (2009). Hepatic cytochrome p450 enzyme alterations in humans with progressive stages of nonalcoholic fatty liver disease. Drug Metab. Dispos. 37, 2087–2094. doi: 10.1124/dmd.09127466

Guo, F., Yang, X., Li, X., Feng, R., Guan, C., Wang, Y., et al. (2013). Nuciferine Prevents Hepatic Steatosis and Injury Induced by a High-Fat Diet in Hamsters. PLoS One 8, e53770. doi: 10.1371/journal.pone.0053770

Han, M. S., Park, S. Y., Shinzawa, K., Kim, S., Lee, M. S., Kun, W. C., et al. (2008). Lysophosphatidylcholine as a deactivator in the lipooxipoptosis of hepatocytes. J. Lipid Res. 49, 84–97. doi: 10.1194/jlr.m700184-1lr0

Jiang, W., Guo, M. H., and Hai, X. (2016). Hepatoprotective and antioxidant effects of lycopeno on non-alcoholic fatty liver disease in rats. World J. Gastroenterol. 22, 10180–10188. doi: 10.3738/wg.v22i46.10180

Kind, T., Wohlgequemuth, G., Lee, D. Y., Lu, Y., Palazoglu, M., Shabaz, S., et al. (2009). FiehnLib mass spectral and retention index libraries for metabolomics based on quadrupole and time-of-flight gas chromatography/mass spectrum. Anal. Chem. 81, 10038–10048. doi: 10.1021/ac9019522

King, A. M., Mullin, L. G., Wilson, I. D., Coen, M., Rainville, P. D., Plumb, R. S., et al. (2019). Development of a rapid profiling method for the analysis of polar analytes in urine using HILIC-MS and ion mobility enabling HILIC-MS. Metabolomics 15, 17. doi: 10.1007/s11306-019-1474-9

Kobyliak, N., and Abenavoli, L. (2014). The role of liver biopsy to assess non-alcoholic fatty liver disease. Rev. Recent Clin. Trials 9, 159–169. doi: 10.2174/1574887109666141216102231

Koo, S. H. (2013). Nonalcoholic fatty liver disease: molecular mechanisms for the hepatic steatosis. Clin. Mol. Hepatol. 19, 210–215. doi: 10.3350/cmh.2013.19.3.210

Li, Z., Agellon, L. B., Allen, T. M., Umeda, M., Jewell, L., Mason, A., et al. (2006). The ratio of phosphatidylcholine to phosphatidylethanolamine influences membrane integrity and steatohepatitis. Cell Metab. 3, 321–331. doi: 10.1016/j.cmet.2006.03.007

Li, Y. T., Cui, H. T., Yang, L., Jin, L. L., Wang, Y. M., Dong, X. Q., et al. (2020). Hua-Zhuo-Kai-Yu decoction inhibits apoptosis in nonalcoholic fatty liver disease. Tradit. Med. Res. 1. doi: 10.12032/TMR20200201157

Lysophosphatidylcholine as a deactivator in the lipooxipoptosis of hepatocytes. J. Lipid Res. 49, 84–97. doi: 10.1194/jlr.m700184-1lr0

Xie, H. L., He, X. Y., You, C., Tao, X., Wang, L. S., Zhang, M. D., et al. (2018). Pharmacokinetics of nuciferine and n-nornuciferine, two major alkaloids from nelumbio nucifera leaves, in rat plasma and the brain. Front. Pharmacol. 9, 902. doi: 10.3389/fphar.2018.00902

Youmosb, Z. M., Golab,M., de Avila, L., Paik, J. M., Srisarda, M., Fukui, N., et al. (2019). The Global Epidemiology of NAFLD and NASH in Patients with type 2 diabetes: A Systematic Review and Meta-analysis. J. Hepatol. 71, 793–801. doi: 10.1016/j.jhep.2019.06.021
Yu, M., Zhu, Y., Cong, Q., and Wu, C. (2017). Metabonomics Research Progress on Liver Diseases. Can. J. Gastroenterol. Hepatol. 2017, 8467192. doi: 10.1155/2017/8467192

Zeng, X. H., Sun, D. M., Yao, N., Chen, Y. X., Cai, D. K., Huang, X. J., et al. (2016). Impaired reverse cholesterol transport and hepatic steatosis contribute to pathogenesis of high fat diet-induced hyperlipidemia in murine models. Trop. J. Pharm. Res. 15, 701–708. doi: 10.4314/tjpr.v15i4.5

Zhang, D. D., Zhang, J. G., Wu, X., Liu, Y., Gu, S. Y., Zhu, G. H., et al. (2015). Nuciferine downregulates Per-Arnt-Sim kinase expression during its alleviation of lipogenesis and inflammatory on oleic acid-induced hepatic steatosis in HepG2 cells. Front. Pharmacol. 6, 238. doi: 10.3389/fphar.2015.00238

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Cui, Li, Cao, Liu, Miao, Fu, Song, Wen, Zhang and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.